Multiple myeloma: New options, new challenges

Mayo Clinic Proceedings

Volumn 81, Issue 7, 2006, Pages 877-879

  Lacy, Martha Q ^a,b  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; THALIDOMIDE; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PATIENT; DRUG EFFICACY; EDITORIAL; HIGH RISK PATIENT; HUMAN; MULTIPLE MYELOMA; PERIPHERAL NERVE; QUALITY OF LIFE; REMISSION; SURVIVAL; TREATMENT PLANNING;

EID: 33745597359     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.7.877     Document Type: Editorial

References (21)

1. Hussein MA, Baz R, Srkalovic G, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-iefractory multiple myeloma. Mayo Clin Proc. 2006;81:889-895.
2. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984;310: 1353-1356.
3. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990;33:86-89.
4. Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase II multicenter randomized trial. Cancer. 2006;106:848-858.
5. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [published correction appears in N Engl J Med. 2000;342-.364]. N Engl J Med. 1999;341:1565-1571.
6. Richardson P, Schlossman R, Jagannath S, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc. 2004;79:875-882.
7. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319-4323.
8. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.
9. Cavo M, Zamagni E, Tosi P, et al, Writing Committee of the Bologna 2002 Study. Superiority of thalidomide and dexamethasone over vincristinedoxorubicin- dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106:35-39.
10. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006 Jan 20;24:431-436. Epub 2005 Dec 19.
11. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005;80:1568-1574.
12. Rajkumar SV. Thalidomide therapy and deep venous thrombosis in multiple myeloma [editorial]. Mayo Clin Proc. 2005;80:1549-1551.
13. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologie malignancies. Blood. 2005 Apr 15;105: 3058-3065. Epub 2004 Dec 30.
14. Kyle RA, Leong T, Li S, et al. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer. 2006;106:1958-1966.
15. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005 Dec 15;106:4050-4053. Epub 2005 Aug 23.
16. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129:776-783.
17. Palumbo A, Bringhen S, Caravita T, et al, Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367: 825-831.
18. Jackson DV, Case LD, Pope EK, et al. Single agent vincristine by infusion in refractory multiple myeloma. J Clin Oncol. 1985;3:1508-1512.
19. Rajkumar SV. Multiple myeloma: the death of VAD as initial therapy. Blood. 2005;106:2-3.
20. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131-3136.
21. Rajkumar SV, Kyle RA. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2005;80:1371-1382.